A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

You may not be if

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Measurable disease according to RECIST criteria version 1.1
• Adequate bone marrow, cardiac, liver and renal function
• Participants with histologically proven Hepatocellular Carcinoma (HC), Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), gastric cancer, malignant melanoma, nonmetastatic and locally controlled PVNS/TGCT
• Participants with known auto-immune disease
• Known or suspected central nervous system (CNS) metastases including leptomeningeal metastasis; participants with radiologically stable, asymptomatic previously irradiated lesion are eligible provided participant is greater than or equal to (\>/=) 4 weeks beyond completing cranial irradiation and \>/= 3 weeks of corticosteroid therapy
• Significant, uncontrolled concomitant diseases, including significant cardiovascular or pulmonary disease
• Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy for bone pain), any investigational agent or immunotherapy within 28 days of first receipt of study drug
• Prior corticosteroids as anti-cancer therapy within minimum of 14 days of first receipt of study drug
• Poorly controlled type 1 or type 2 diabetes mellitus
• Prior toxicities from chemotherapy or radiotherapy which have not regressed to Grade less than or equal to (\</=) 1 severity National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 or later versions
• Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection
• Pulmonary embolism or any other thrombo-embolic event within 6 months prior to study entry
• History of hematological malignancy within the last 5 years prior to study entry
• Participant requires high dose corticosteroid treatment ( i.e. greater than (\>) 20 mg dexamethasone a day or equivalent for \> 7 consecutive days)
• Any surgical procedure, including the required baseline tumor biopsy, within less than 14 days of first receipt of study drug. Major surgery within 28 days of first receipt of study drug
• Pregnant or lactating women